Highlights from

WCD 2019

World Congress of Dermatology

Milan 10-15 June 2019

IL-17A inhibition effective in hidradenitis suppurativa

Hidradenitis suppurativa (HS) is a debilitating condition with a need for effective and safe treatments. A novel fully human monoclonal antibody against interleukin (IL)-17A, study name CJM112, was previously found to have a similar efficacy in psoriasis compared with other anti-IL17 antibodies. A 16-week proof-of-concept trial in HS showed that more patients responded to CJM112 vs placebo [1].

Biologics offer a promising nonsurgical approach in HS, particularly in disease with highly pronounced inflammation. Studies have shown increased expression of a range of cytokines in lesional HS skin, including IL-17 [2]. Prof. Alexa Kimball (Harvard Medical School, USA) and colleagues investigated 3 agents that block IL-17, namely secukinumab, brodalumab, and ixekizumab, for several dermatological indications. In addition, several agents which target the IL-17–TH17 pathway, such as CJM112, are currently investigated.


This multicentre, randomised, double-blind, placebo-controlled trial, evaluated whether CJM112 is effective in the treatment of adult patients with moderate-to-severe HS. During period 1, a high dose of CJM112 (300 mg) subcutaneous was compared with placebo. The Hidradenitis Suppurativa Physician’s Global Assessment (HS-PGA) response at week 16, the primary endpoint of the study, was 32% with CJM112 vs 13% with placebo. The decrease in inflammatory lesions, i.e. abscesses, inflammatory nodules, and draining fistulae, was 56% with CJM112 compared with 30% for placebo.


CJM112 was generally well tolerated. The overall safety profile of CJM112 was similar to the placebo group. No deaths were reported during this study. Two patients from the placebo group reported severe adverse events: one case of angina pectoris and one of groin abscess. In Extension Period 2, those patients who entered into the study with placebo were allowed to continue with CJM112.

  1. Kimball AB, et al. Hidradenitis Suppurativa Responds to a Novel Anti-IL17 Antibody (CJM112) in a Controlled Clinical Trial vs Placebo. Poster presented at the World Congress of Dermatology 2019, 10-15 June, Milan, Italy.
  2. Matusiak L. et al. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. JAAD 2017; 76(4): 670-675.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.